Canaccord Genuity Sticks to Their Buy Rating for Candel Therapeutics (CADL)
I'm PortAI, I can summarize articles.
Canaccord Genuity analyst John Newman maintained a Buy rating for Candel Therapeutics (CADL) with a price target of $25.00. Newman, a 2-star analyst, has an average return of 0.1% and a 39.16% success rate. Candel Therapeutics also received a Buy rating from H.C. Wainwright, while Bank of America Securities maintained a Hold rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments